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The post-translational modification AMPylation is emerging as a significant regulatory mechanism 
in both prokaryotic and eukaryotic biology. This process involves the covalent addition of an 
adenosine monophosphate to a protein resulting in a modified protein with altered activity. 
Proteins capable of catalyzing AMPylation, termed AMPylators, are comparable to kinases in that 
they both hydrolyze ATP and reversibly transfer a part of this primary metabolite to a hydroxyl side 
chain of the protein substrate. To date, only four AMPylators have been characterized, though 
many more potential candidates have been identified through amino acid sequence analysis 
and preliminary in vitro studies. This modification was first discovered over 40 years ago by 
Earl Stadtman and colleagues through the modification of glutamine synthetase by adenylyl 
transferase; however research into this mechanism has only just been reenergized by the studies 
on bacterial effectors. New AMPylators were revealed due to the discovery that a bacterial 
effector having a conserved Fic domain transfers an AMP group to protein substrates. Current 
research focuses on identifying and characterizing various types of AMPylators homologous 
to Fic domains and adenylyl transferase domains and their respective substrates. While all 
AMPylators characterized thus far are bacterial proteins, the conservation of the Fic domain 
in eukaryotic organisms suggests that AMPylation is omnipresent in various forms of life and 
has significant impact on a wide range of regulatory processes.
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sequence and structural features. AMPylation by these domains 
has been demonstrated to have roles in both the pathogenicity of 
bacterial species and in endogenous metabolic regulation. A signifi-
cant amount of structural and kinetic data about the mechanism 
of AMPylation by both domains has been elucidated. Herein are 
described the mechanisms for known AMPylators, including their 
substrates, structural features, and enzyme kinetics.
The Fic and adenylyl TransFerase domains:  
Two oF a kind
The Fic domain is a member of the Fido (Fic/doc) protein super-
family and is widely conserved across most non-plant species. 
Similarities in catalytic motif and structural organization led to the 
merging of the Fic and doc families (Kinch et al., 2009). The Fic and 
doc domains share the conserved HPFx[D/E]GN[G/K]R motif, in 
which the invariant histidine residue has proven to be essential for 
AMPylation activity in Fic proteins (Luong et al., 2010) and cytotox-
icity in doc (Garcia-Pino et al., 2008). Fic and doc also share similar 
structural features, but doc is not known to catalyze AMPylation. 
Doc has been shown to catalyze its toxic phenotype in Escherichia 
coli by associating with the 30S ribosomal subunit and inhibiting 
translational elongation (Lehnherr et al., 1993; Liu et al., 2008). In 
terms of distribution, the comprehensive protein family database 
Pfam currently identifies the Fic domain in over 2,000 bacterial 
proteins that are cataloged among 984 bacterial species, including 
human pathogens and commensals in addition to environmental 
bacteria. Proteobacteria and firmicutes constitute approximately 
one-half and one-quarter of this number, respectively, and maintain 
a roughly 2:1 overall ratio of Fic proteins per species. In contrast, 
only 59 Fic proteins from 43 eukaryotic species have been identified, 
inTroducTion
The post-translational modification AMPylation, previously 
referred to as adenylylation, was first discovered by Earl Stadtman 
et al. in the 1960s when he observed that a tyrosine residue of 
Escherichia coli glutamine synthetase was modified with AMP 
(Brown et al., 1971). This modification is defined as the stable 
and reversible covalent addition of an adenosine mono phosphate 
group to a hydroxyl side chain of a protein (Figures 1A,B). While 
AMPylation has only been observed to modify threonine and 
tyrosine residues, it is likely that serine can function as a target as 
well. AMPylation is distinct from transient adenylylation events 
that involve the addition of AMP to the protein targets and use 
the energy of ATP to drive an enzymatic reaction (e.g., processes 
like ubiquitin activation (Worby et al., 2009; Yarbrough and Orth, 
2009; Luong et al., 2010) or prokaryotic thiamine and molybdenum 
biosynthesis (Lake et al., 2001; Duda et al., 2005).
In pathogenicity, AMPylators act as bacterial effectors that are 
translocated into eukaryotic host cells by Type III or IV Secretion 
Systems (T3SS or T4SS) (Broberg and Orth, 2010) or a two-partner 
secretion system (Jacob-Dubuisson et al., 2001). They typically 
disable the cell by AMPylating components of essential signal-
ing pathways, such as the regulation of the actin cytoskeleton by 
Rho GTPases (Yarbrough et al., 2009), and alter their function. In 
metabolism, the regulation of glutamine synthetase through the 
addition and removal of AMP by glutamine synthetase adenylyl 
transferase (GS-ATase) is a well characterized part of the complex 
regulation of nitrogen levels in the bacterial cell, and represents an 
important metabolic function for AMPylation (Brown et al., 1971; 
Jiang et al., 1998). The Fic and adenylyl transferase domains com-
prise the current known AMPylators and each have distinct primary 
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The adenylyl transferase domain (GlnE family) is part of the 
larger nucleotidyl transferase protein family and in addition to the 
Fic domain has been identified as capable of catalyzing AMPylation. 
It is characterized by a conserved G-X
11
-D-X-D motif, of which 
the aspartate residues have been shown to be essential for the 
AMPylation activity (Figure 1B) (Jiang et al., 2007a; Muller et al., 
2010). This domain has been identified in more than 1,400 bacterial 
proteins among 685 bacterial species, of which the large majority 
are proteobacteria (Finn et al., 2010). Two members of this family 
have been identified as AMPylators: initially with GS-ATase and 
more recently with the characterization of the Legionella pneu-
mophila effector DrrA/SidM (Muller et al., 2010).
amPylators in PaThogeniciTy
Secretion systems are often used by Gram negative bacterial species 
to translocate virulence factors, also called effectors, into eukaryo-
tic cells. These proteins typically subvert cellular processes during 
infection by locking the target into an active or inactive state, often 
by mimicking a normal cellular signaling mechanism. While Gram 
negative bacteria have been shown to use a broad arsenal of effectors 
with different mechanisms, effectors from three different species 
have been shown to use AMPylation (Table 1). The proteins VopS, 
IbpA, and DrrA are secreted into eukaryotic cells from Vibrio para-
haemolyticus (V. para), H. somni, and L. pneumophila, respectively, 
and have been demonstrated to AMPylate host GTPases, resulting 
in changes in the actin cytoskeleton (Worby et al., 2009; Yarbrough 
et al., 2009; Muller et al., 2010).
gTPases: a common TargeT oF amPylators
The families of Rho, Rab, and Arf GTPases have fundamental 
roles in actin cytoskeleton dynamics and vesicular trafficking 
and control cellular processes such as phagocytosis in the host 
cell. During infection, the pathogen must control the inhibition 
or induction of host cell phagocytosis to prevent or promote its 
internalization. Thus, small G proteins involved in these proc-
esses are often the target of numerous bacterial virulence factors 
such as bacterial surface proteins, effectors, and toxins (Boquet 
and Lemichez, 2003). The GTPase activating protein (GAP) and 
GTPase exchange factor (GEF) activity of YopE from Yersinia spp. 
and SopE from Salmonella enterica target Rho GTPases, while the 
aforementioned DrrA has a modular domain with GEF activity 
targeted toward Rab GTPases (Hardt et al., 1998; Nagai et al., 2002). 
A large number of post-translational mechanisms are employed 
by bacterial effectors to modify and inhibit GTPases, including 
GAP, GEF, ADP-ribosylation, and proteolytic cleavage (Boquet 
and Lemichez, 2003).
Protein AMPylation by effectors VopS, IpbA, and DrrA have pro-
vided a novel biochemical mechanism used during bacterial patho-
genesis that is distinct from those previously described. Protein 
AMPylation by these effectors occurs in the conserved switch 1 
or switch 2 regions of GTPases and sterically hinders downstream 
binding of Rho GTPase substrates. Similarly, clostridial toxins such 
as ToxA and ToxB from C. difficile have glucosyltransferase activ-
ity that mediates the covalent modification of a threonine resi-
due in the switch 1 region of Rho GTPases with glucose (Richard 
et al., 1999). This is the same threonine residue AMPylated by 
VopS (Yarbrough et al., 2009). Modification by glucosylation or 
and metazoans Drosophila menanogaster, Caenorhabditis elegans, 
mice, and humans contain only one copy each (Finn et al., 2010). 
Additionally, the Fic domain has been cataloged in 49 archaeal pro-
teins and in seven viral proteins. It is very rare for one protein to 
contain more than one Fic domain, though the Histophilus somni 
protein IbpA is one of the few exceptions with two.
Characterization of the Fic domain has thus far progressed mostly 
with bacterial effector proteins, though in vitro auto-AMPylation 
activity has been observed for both the human protein HYPE 
(Worby et al., 2009) and the Drosophila protein CG9523 (Kinch 
et al., 2009). Speculation on the function of the Fic domain in 
eukaryotic proteins has centered around their domain organization, 
which is well covered in Kinch et al. (2009). Briefly, bioinformatic 
analysis of Fic proteins has revealed its association with DNA bind-
ing domains, transmembrane regions, a variety of protein–protein 
interaction and enzymatic domains, and perhaps most interestingly, 
a low-density lipoprotein receptor domain class A (LDL) (Kinch 
et al., 2009). This association with the LDL receptor domain could 
imply a role in cholesterol metabolism in eukaryotes. Despite these 
insights, the only two Fic proteins that have been characterized are 
the secreted bacterial effectors VopS and IbpA (Worby et al., 2009; 
Yarbrough et al., 2009).
FIGure 1 | AMPylation in pathogenicity. (A) The Fic effector AMPylators 
VopS (shown) and IbpA are secreted into eukaryotic cells and modify a 
threonine or tyrosine residue on the Switch 1 loop of Rho family GTPases, 
sterically blocking their association with downstream substrates like PAK and 
rhotekin. (B) The adenylyl transferase effector AMPylator DrrA catalyzes the 
exchange of GDP for GTP in the GTPase Rab1b through its GEF domain (not 
shown) and AMPylates a tyrosine in the Switch 2 loop, preventing its 
association with GAPs. (C, D) HeLa cells transfected with mock vector (C) or 
with VopS (D), visualized with confocal microscopy for rhodamine phalloidin 
stain (actin, red) and Hoechst stain (DNA, blue).
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binding and internalization into host eukaryotic cells after secre-
tion from the bacterium (Zekarias et al., 2010). IbpA also has two 
Fic domains at the C-terminal region that are responsible for its 
cytotoxicity (Worby et al., 2009). This cytotoxicity is a result of 
the IbpA Fic domains’ AMPylation of Rho family GTPases, which 
blocks their binding to downstream substrates like rhotekin and 
PAK. Cells transfected with the Fic domains of IbpA have a rounded 
phenotype similar to those transfected with VopS (Figure 1C,D). 
However, IbpA’s AMPylation of the switch 1 region in GTPases 
occurs on a tyrosine, rather than a threonine.
drra
The most recently characterized AMPylator, DrrA, is yet another 
bacterial effector, but contains an adenylyl transferase domain 
rather than a Fic domain Muller et al. (2010). This virulence fac-
tor is secreted from L. pneumophila, an intracellular pathogen 
that survives in Legionella containing vacuoles (LCV) in the cell. 
Legionella uses a T4SS to secrete proteins from the LCV into the 
host cell. DrrA is composed of three domains: an N-terminal ade-
nylyl transferase domain, a central guanine nucleotide exchange 
factor (GEF) domain, and a C-terminal phosphatidylinositol-4 
 phosphate-  binding (P4M) domain (Murata et al., 2006; Brombacher 
et al., 2009). The first domain of DrrA very closely resembles the 
C-terminal adenylyl transferase domain of GS-ATase (Figure 2) and 
contains the conserved G-X
11
-D-X-D motif (Muller et al., 2010). 
The GEF domain is capable of catalyzing the exchange of GDP for 
GTP in the GTPase Rab1b, which plays a role in the regulation of 
vesicular transport from the endoplasmic reticulum (Murata et al., 
2006). The P4M domain anchors the effector to the cytoplasmic 
side of the LCV membrane (Brombacher et al., 2009). DrrA has 
been shown to hijack the function of Rab1b by locking it into its 
GTP-bound active state through the function of the DrrA GEF 
and adenylyl transferase domains. The GEF domain of DrrA binds 
AMPylation sterically hinders downstream substrate binding, 
inhibiting the function of Rho GTPases and leading to breakdown 
of actin cytoskeleton signaling.
Vops
Vibrio parahaemolyticus is an extracellular Gram negative bacte-
rium that causes gastroenteritis from eating undercooked seafood 
(Daniels et al., 2000a,b). An essential virulence factor for many 
Gram negative pathogens, including V. para, is the T3SS, a needle-
like structure that extends from the bacterium and penetrates a 
host cell to inject effectors (Makino et al., 2003). V. para secretes 
a variety of effectors, each of which individually are responsible 
for a broad range of phenotypes in the infected cell. VopS was 
the first example of a Fic domain functioning as an AMPylator. 
VopS modifies threonine 35 on the switch 1 region of the Rho 
family GTPases resulting in GTPases that are unable to bind to 
downstream effectors like p21 activated kinase 1 protein (PAK) 
(Yarbrough et al., 2009) (Figure 1A). The loss of this interaction 
disables the host cell’s control of the actin cytoskeleton, which leads 
to cell rounding (Figure 1C,D).
ibpa
IbpA is secreted from H. somni, an obligate and opportunistic 
pathogen in cattle (Martin et al., 1998). H. somni is a Gram nega-
tive bacterium that commonly infects the respiratory epithelium 
of cattle and is often responsible for bovine respiratory disease 
complex, an economically important cause of bovine mortality. 
H. somni secretes immunoglobulin binding proteins through a 
two-partner secretion system, which have been shown to be an 
important virulence factor and are likely to mediate bacterial adhe-
sion to the host epithelium (Corbeil et al., 1997; Jacob-Dubuisson 
et al., 2001). One of these is IbpA, which contains putative adhesin 
domains at the N-terminal region that are predicted to mediate its 
Table 1 | Fic and adenylyl transferase AMPylators.
Kingdom Name Organism Target Function Structure references
Fic domain catalytic 
motif: HPFx[D/E]
GN[G/K]R







PDB ID 3LET Yarbrough et al. (2009)





PDB ID 3N3U 
and 3N3V 
Worby et al. (2009), 
Xiao et al. (2010), 






No Pan et al. (2008), Roy 
and Mukherjee (2009)
Eukaryotic HYPE Homo sapiens ? ? No Worby et al. (2009)
CG9523 Drosophila 
melanogaster












PDB ID IV4A 
and 3K7D
Mangum et al. (1973), 









PDB ID 3NKU Muller et al. (2010), 
Murata et al. (2006)
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synthesize glutamine. This modification is controlled by a complex 
regulatory system, in which the PII protein controls the activity of 
GS-ATase, which in turn controls the activity of glutamine synthetase 
via the addition or removal of AMP. PII activity is dependent on the 
intracellular concentrations of the metabolites α-ketoglutarate and 
glutamine, which reflect the current state of nitrogen metabolism 
in the cell. When levels of intracellular glutamine are low during 
nitrogen starvation, the PII protein exists primarily as PII-UMP. 
In the presence of PII-UMP and high α-ketoglutarate, GS-ATase is 
stimulated to remove AMP from glutamine synthetase, allowing the 
synthesis of glutamine (Jiang et al., 1998). PII is mostly unmodified 
when glutamine levels are high, during which GS-ATase transfers 
AMP to Y397 of glutamine synthetase, inhibiting its activity (Jiang 
et al., 1998). It has become clear, more than 40 years after its discov-
ery, that GS-ATase catalyzes the same reaction that has since been 
termed AMPylation. Thus, the GS-ATase acts as the only example 
of an endogenous signaling system that is regulated by AMPylation, 
a reversible post-translational modification.
kineTic and sTrucTural FeaTures oF amPylators
enzyme kineTics
Enzymatic studies with VopS enzyme and mutants at conserved resi-
dues in the Fic domain provided insight into the catalytic mechanism 
used by the Fic domain to modify Rho GTPases with AMP (Luong 
et al., 2010). Steady-state studies revealed the apparent affinity for 
ATP binding and the catalytic contribution of conserved Fic residues 
toward AMPylation (Luong et al., 2010). The histidine of the Fic 
motif was shown to be the most critical residue, acting as a general 
base during catalysis (Luong et al., 2010). Based on these kinetic 
studies predictions were made about the coordinate binding of sub-
strates where Fic motif residues and the beta/hairpin loop element 
are important for ATP and protein substrate binding, respectively. 
Kinetic studies that supported a direct transfer mechanism were vali-
dated by the crystal structures of the Fic region from IbpA alone and 
in complex with Cdc42 Rho GTPase (see below) (Xu et al., 2009).
Both DrrA and GS-ATase contain the catalytic motif G-X
11
-D-X-D, 
with each aspartate coordinating a magnesium ion. Mutations of the 
conserved D110A and D112A in DrrA was demonstrated to abrogate 
AMPylation activity (Muller et al., 2010). The conserved aspartate 
residues D701 and D703 of GS-ATase were also shown to be critical 
for activity in steady-state kinetic studies (Jiang et al., 2007a). Further 
mechanistic studies with GS-ATase supported a sequential reaction 
mechanism where enzyme, substrate, and ATP form a ternary com-
plex for catalysis, which matches the findings of similar studies with 
VopS and GTPases (Jiang et al., 2007b; Luong et al., 2010).
sTrucTural FeaTures
Structures of Fic-containing proteins have been determined from 
the structural genomic consortium and include Helicobacter pylori 
[PDB ID 2F6S], Bartonella henselae [PDB ID 2JK8], Shewanella 
oneidensis [PDB ID 3EQX], Bacteroides thetaiotaomicron [PDB ID 
3CUC], and Neisseria meningitidis [PDB ID 2GO3] (Kinch et al., 
2009; Luong et al., 2010). However, the endogenous substrates of 
these proteins have remained elusive. Protein structures of VopS 
[PDB ID 3LET] and IbpA [PDB ID 3N3U and 3N3V] with their Fic 
domain have been elucidated and these enzymes have been shown 
to AMPylate the Rho GTPase family on a threonine and tyrosine 
residue, respectively (Luong et al., 2010; Xiao et al., 2010). The 
Rab1b and activates it by exchanging GDP for GTP. The adenylyl 
transferase domain then AMPylates the Y77 residue of the Switch 
2 region of Rab1b, which blocks its interaction with GAPs and 
prevents the hydrolysis of GTP. Due to DrrA’s localization to the 
LCV membrane through its P4M domain, it is thought that the 
permanently activated, AMPylated and prenylated GTP-Rab1b 
will be localized with DrrA at the LCV and dominantly target ER 
vacuoles to the LCV (Muller et al., 2010). Transfection of DrrA into 
eukaryotic cells causes a rounding phenotype similar to VopS and 
IbpA, albeit by a distinct mechanism (Figure 1C,D).
ankX
Legionella pneumophila also contains another likely AMPylator, the 
Fic protein effector AnkX. It is one of a group of effectors containing 
ankyrin repeat homology domains (ARHDs) that are translocated 
into a host cell via the T4SS. Though its molecular target remains 
unknown, it has been demonstrated to cause fragmentation of the 
Golgi apparatus and inhibit secretory transport after transfection 
in mammalian cells (Pan et al., 2008; Roy and Mukherjee, 2009). 
AMPylation by AnkX has not been fully demonstrated, but the 
induction of Golgi fragmentation is absent during transfections 
with truncations lacking the Fic domain or a point mutant of the 
catalytically essential histidine residue of the Fic domain, suggesting 
that AMPylation is responsible.
amPylators in regulaTory PaThways
gs-aTase (glne)
GS-ATase is involved in metabolic regulation and was the first 
enzyme characterized to regulate another protein by modification 
with AMP. While it was first characterized in E. coli, the protein is 
conserved across many bacterial species and solved structures exist 
for both the E. coli (PDB ID IV4A and 3K7D) (Xu et al., 2004, 2009) 
and Mycobacterium tuberculosis homologues (PDB ID 2WHI and 
2WGS) (Nilsson et al., 2009). The E. coli GS-ATase contains two ade-
nylyl transferase domains that catalyze the removal and addition of 
AMP to glutamine synthetase at its N- and C-terminus, respectively. 
GS-ATase plays a role in nitrogen metabolism by controlling the 
AMP modified state of glutamine synthetase and thus its ability to 
FIGure 2 | Domain architecture of the Fic-containing protein VopS and 
the adenylyl transferase region of DrrA. The Fic domain is highlighted in red 
with the non-conserved subdomain in white. Black spheres in VopS display 
the conserved catalytic histidine of the Fic motif. The DrrA adenylyl transferase 
region is colored green and black spheres correspond to the two conserved 
aspartates in adenylyl transferases.
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AMPylating region of GS-ATase are very similar with a root mean 
square deviation (RMSD) of 2.4 Å with both regions sharing only 
24% sequence identity. Positions of active site residues involved 
in ATP binding and catalysis are conserved in both structures (Xu 
et al., 2004). Differences in secondary structural elements and con-
formations at the active site help explain differences in enzymatic 
activity between the two structurally homologous domains. No 
other bona fide de-AMPylases have been discovered.
A phosphodiester bond covalently links AMP and a hydroxyl 
chain residue of a protein, and it is possible that the phosphodi-
esterase (PDE) family of enzymes could potentially remove AMP 
from AMPylated proteins. Supporting this notion, the promiscu-
ous snake venom PDE was demonstrated to remove AMP from a 
modified tyrosine in Rac1 GTPase (Worby et al., 2009).
concluding remarks
The role of AMPylation is in its infancy and many questions about the 
nature and diversity of this post-translational modification remain 
to be answered. First and foremost is the role of AMPylation in 
endogenous eukaryotic signaling. Bacterial AMPylators have shown 
a preference for GTPase substrates, but no biologically relevant data 
supports GTPases as substrates for eukaryotic Fic domain-contain-
ing proteins (Worby et al., 2009). As shown previously, the domain 
organization of several eukaryotic Fic proteins suggests membrane 
localization and a role in metabolism or stress response. Secondly, 
bioinformatic studies show the existence of Fic domains in bacteria 
as housekeeping genes. In fact the name “Fic” is derived from genetic 
observation (filamentation induced by cAMP) whereby the cell mor-
phology of E. coli lacking a Fic protein was altered in the presence of 
cAMP. Understanding the role of Fic domains in the bacterial host 
will provide valuable insight for many Fic domain-containing pro-
teins. A third important aspect of this field of research should include 
understanding the mechanism of de-AMPylation. Undoubtedly, 
the role of de-AMPylases will be important for our understanding 
the regulatory cycle of this post-translational modification. This is 
clearly the case with the GS-ATase, in which the N-terminal adenylyl 
transferase domain is a de-AMPylase and is intimately involved in 
the regulation of a metabolic system. It remains to be determined 
if de-AMPylation is catalyzed by other adenylyl transferases, phos-
phodiesterases, or another yet-to-be-discovered enzyme.
Further research into the crosstalk between the vast numbers 
of post-translational modifications on proteins is essential for 
understanding their impact on cellular signaling. Although the 
reductionist approach to cellular signaling has been incredibly 
productive in increasing our understanding of cellular signaling, 
it has also made clear how little we understand about the complex-
ity of most, if not all signaling pathways. The manner in which 
different post-translational modifications compete for the same 
and proximal residues is poorly understood but likely represents 
an important aspect of signaling. This aspect of signaling becomes 
ever more daunting as more reversible post-translational modifi-
cations are discovered. When one considers that AMPylation can 
modify the same residues as phosphorylation, it becomes clear that 
the  significance of AMPylation in signaling will continue to grow. 
Tackling the regulatory and molecular mechanisms of AMPylation, 
as is being done with other modifications such as acetylation, meth-
ylation, glycosylation, and lipidation, is imperative for understand-
ing cellular signaling.
Fic domain family displays a conserved topology, with a central 
two-helix bundle encircled peripherally by up to 6 helices. The 
Fic motif HPFx[D/E]GN[G/K]R lies within the loop connecting 
the two central helices. A conserved beta hairpin/loop structural 
element positioned near the Fic motif is also present in all solved 
structures (Kinch et al., 2009). In addition to their Fic domain most 
of the proteins contain topologically diverse subdomains, which 
mediates their unique biological function.
The initial crystal structure of the Fic region from VopS and the 
subsequent structures from native IbpA and in complex with Cdc42 
Rho GTPase have revealed insights into the structural mechanism 
of protein substrate and ATP binding (Figure 2) (Luong et al., 2010; 
Xiao et al., 2010). The structure of IbpA–Cdc42 is an end-product 
complex with its tyrosine AMPylated and mimics the GDI-bound 
state of Rho GTPases. Extensive contacts are observed between the 
enzyme and substrate, which includes the conserved switch 1 and 
switch 2 regions of Cdc42. As predicted by the bioinformatics stud-
ies by Kinch et al., the beta hairpin/loop of Fic domains coordinates 
binding of substrates. The beta/hairpin loop of IbpA interacts in 
strand-to-strand fashion with the switch 1 region of Cdc42. The 
beta/hairpin loop is disordered in the native structure of IbpA but, as 
predicted based on previously solved Fic domains (Kinch et al., 2009; 
Luong et al., 2010), transition to ordered state upon protein sub-
strate binding. Structural rearrangements also take place within the 
non-conserved subdomain of IbpA and support in protein substrate 
binding (Xiao et al., 2010). The VopS non-conserved subdomain was 
further demonstrated to have a role in protein substrate binding 
(Xiao et al., 2010). The Fic structure of BepA [PDB ID 2JK8] from B. 
henselae shows residues Asp/Glu and Asn of the Fic motif have roles in 
coordination of magnesium pyrophosphate (Luong et al., 2010).
The structure of the AMPylation domain of GS-ATase from E. coli 
was revealed to be structurally homologous to the nucleotidyl trans-
ferase family (Xu et al., 2009). This family possesses a core alpha/
beta-fold comprised of a three-stranded mixed beta sheet flanked 
by four alpha helices (Kuchta et al., 2009). The N-terminal region 
of L. pneumophilia DrrA (residues 9-218) was determined by X-ray 
crystallography and is structurally similar to GS-ATase (Figure 2) 
(Muller et al., 2010). Concurrently a structure of AMPylated Rab1b 
modified at switch 2 tyrosine-77 GppNHp bound was also solved 
(Muller et al., 2010). DrrA was demonstrated to disrupt vesicular 
trafficking through AMPylation of Rab1b GTPase. There is no DrrA 
Rab1b GTPase complex structure available yet, but structure com-
parisons of modified Rab1b with native structure of closely related 
Rab3A implies AMP is not inducing structural rearrangements but 
inhibits downstream signaling by sterically hindering the binding 
of native substrates (Muller et al., 2010).
de-amPylation
GS-ATase is a single enzyme that catalyzes two reactions, the de-
AMPylation and AMPylation of glutamine synthetase (Jiang et al., 
2007a). The domains for each activity are located at its N- and 
C-terminus, respectively. The de-AMPylation activity of GS-ATase 
removes AMP from modified glutamine synthetase and forms ADP 
and unmodified glutamine synthetase. Similar to the AMPylation 
domain, the de-AMPylase region of GS-ATPase is structurally 
homologous to the nucleotidyl transferase family and contains 
the G-X
11
-D-X-D motif (Xu et al., 2004). Structural comparisons 
revealed the N-terminal de-AMPylating domain and the C-terminal 
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